PureTech Health plc
PRTC
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis inā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$17.58
Price-0.69%
-$0.12
1Y
Price
Market Cap
$424.835m
Small
Price/Earnings 3y Avg5y Avg
10.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2498.1%
EBITDA Margin-2409.8%
Net Profit Margin-2482.0%
Free Cash Flow Margin-2498.1%
EBITDA Margin-2409.8%
Net Profit Margin-2482.0%
Free Cash Flow MarginRevenue
$6.345m
+31.4%
1y CAGR+45.2%
3y CAGR+14.2%
5y CAGREarnings
-$31.464m
-158.8%
1y CAGR-2.6%
3y CAGR+2.3%
5y CAGREPS
-$0.65
-132.5%
1y CAGR+5.8%
3y CAGR+8.0%
5y CAGRBook Value
$369.025m
$553.242m
Assets$184.217m
Liabilities$20.919m
DebtDebt to Assets
3.8%
-1x
Debt to EBITDAFree Cash Flow
-$220.437m
-64.0%
1y CAGR-16.4%
3y CAGR-14.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company